Egypt’s Gennecs Pharmaceuticals is in the process of establishing a multi-vaccine production facility in the country in addition to introducing a vaccine research centre at a total investment of USD 150 million. GennVax, which will be established by Gennecs team, would include global specialists in vaccines and top-notch trailblazers from all over the world with the right exclusive tech transfer providers assuring all production lines to be WHO PQ & European GMP accredited and in analogous with appropriate R&D technologies.
- The biggest full production cycle vaccines facility in the region would be catering to Africa and the MEA region.
- Full vaccines portfolio for current NPIs (Non-pharmaceutical interventions) requirements and for future modernization across the region.
- Applying the highest vaccine manufacturing technologies with a strong data infrastructure.
Nihal Dahaba, Co-Founder & General Manager of Emerging Markets told Zawya Projects that the land for the vaccine plant has been acquired a most important industrial zone. The project would be implemented in partnership with stakeholders from the UAE and Saudi Arabia, Dahaba said without mentioning the zone.
Dahaba also did not disclose the production capacity of the facility but said it would be built in two phases with Phase 1, which comprises packaging, scheduled to be completed by 2026, while Phase 2, which includes actual vaccine production, would be completed by 2029.
She stated that the plant’s concept design has been finalised by a specialist Italian firm, which is now at work on its comprehensive design.
Dahaba said the company would primarily target the domestic market, and after acquiring international certifications, will begin exports to African countries.
GennVax will play a role of a hub in securing all African demand from vaccines. WHO roadmap for Africa is to reach 60 percent of required vaccines to be manufactured locally by 2040. Egypt has the most innovative pharmaceutical industry infrastructure within the region. Egypt is considered the biggest birth group with the largest population in the GAVI allies. It is the biggest direct-procurement country in the region.
Gennecs is the pharmaceutical arm associated from El Daba Holding, an internationally announced swiftly growing conglomerate in Egypt, partnering with local and international investors that leverage their regional and global outreach.
Gennecs group is acting as a local / regional representative and the partner of choice for over ten top global pharmaceutical manufacturers and distributors, creating the biggest portfolio within the region. The company portfolio comprises several top vaccine manufacturers like Moderna. Gennecs team is designed of a group of leading global specialists who participated in the establishment of top vaccine facilities across the world, led by Dr. Nibal Dahaba with the legacy in shaping and modernizing regional NIPs across the MEA or Ministry of External Affairs.